Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning ...

The debate between CAR T-cell therapy and bispecific antibodies is not a rivalry but a question of sequencing, ...

Anne Wojcicki, former chief executive of 23andMe, won a bid to acquire the genetic testing company she founded in a second ...

The California-based nonprofit founded by the former 23andMe CEO is set to close the $305 million deal in coming weeks.

Anne Wojcicki is set to regain control of 23andMe after a $305 million bid from a nonprofit she controls topped Regeneron ...

Regeneron is backing away from buying the DNA-testing company after a nonprofit controlled by co-founder Wojcicki made a ...

In this week’s edition of InnovationRx, we look at the dangers of RFK Jr.’s vaccine advisory committee, how Trump’s visa ban ...

This was the stock's second consecutive day of losses.

Regeneron did not bid higher on the genetic testing company because of “its assessment of 23andMe’s remaining value,” ...

In combination with Eli Lilly’s tirzepatide, marketed as Zepbound for obesity, Scholar Rock’s monolonal antibody helped ...

This trial evaluated the safety and efficacy of the combination of Regeneron’s Lynozyfic (linvoseltamab), a B-cell maturation ...

Scholar Rock said on Wednesday a combination of its experimental drug and Eli Lilly's weight-loss treatment Zepbound helped overweight patients preserve significantly more lean mass in a mid-stage ...